Hormone receptor-positive breast cancer (HR+ BC) accounts for the majority of breast cancer cases and is primarily treated using endocrine therapies, including selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and selective estrogen receptor degraders (SERDs). The gene discussed is ESR1; the disease is breast cancer.